5/30
08:54 am
fdmt
4DMT to Present Interim Data from Aerosolized 4D-710 Phase 1/2 AEROW Clinical Trial for Cystic Fibrosis at 47?? European Cystic Fibrosis Conference [Yahoo! Finance]
Low
Report
4DMT to Present Interim Data from Aerosolized 4D-710 Phase 1/2 AEROW Clinical Trial for Cystic Fibrosis at 47?? European Cystic Fibrosis Conference [Yahoo! Finance]
5/30
08:00 am
fdmt
4DMT to Present Interim Data from Aerosolized 4D-710 Phase 1/2 AEROW Clinical Trial for Cystic Fibrosis at 47?? European Cystic Fibrosis Conference
Low
Report
4DMT to Present Interim Data from Aerosolized 4D-710 Phase 1/2 AEROW Clinical Trial for Cystic Fibrosis at 47?? European Cystic Fibrosis Conference
5/13
08:09 am
fdmt
4D Molecular Therapeutics, Inc. (NASDAQ: FDMT) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $36.00 price target on the stock.
Low
Report
4D Molecular Therapeutics, Inc. (NASDAQ: FDMT) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $36.00 price target on the stock.
5/11
09:34 am
fdmt
We're Interested To See How 4D Molecular Therapeutics (NASDAQ:FDMT) Uses Its Cash Hoard To Grow [Yahoo! Finance]
Low
Report
We're Interested To See How 4D Molecular Therapeutics (NASDAQ:FDMT) Uses Its Cash Hoard To Grow [Yahoo! Finance]
5/11
09:34 am
fdmt
4D Molecular Therapeutics First Quarter 2024 Earnings: US$0.66 loss per share (vs US$0.88 loss in 1Q 2023) [Yahoo! Finance]
Low
Report
4D Molecular Therapeutics First Quarter 2024 Earnings: US$0.66 loss per share (vs US$0.88 loss in 1Q 2023) [Yahoo! Finance]
5/9
04:24 pm
fdmt
4DMT Reports First Quarter 2024 Financial Results and Operational Highlights [Yahoo! Finance]
Low
Report
4DMT Reports First Quarter 2024 Financial Results and Operational Highlights [Yahoo! Finance]
5/9
04:05 pm
fdmt
4DMT Reports First Quarter 2024 Financial Results and Operational Highlights
Low
Report
4DMT Reports First Quarter 2024 Financial Results and Operational Highlights
5/8
12:30 pm
fdmt
SHAREHOLDER ALERT: Kaskela Law LLC Announces Investigation of 4D Molecular Therapeutics, Inc. (FDMT) and Encourages Investors to Contact the Firm
Low
Report
SHAREHOLDER ALERT: Kaskela Law LLC Announces Investigation of 4D Molecular Therapeutics, Inc. (FDMT) and Encourages Investors to Contact the Firm
5/7
08:00 am
fdmt
4DMT to Participate in Upcoming Investor Conference
Low
Report
4DMT to Participate in Upcoming Investor Conference
5/1
11:25 am
fdmt
4D Molecular Therapeutics, Inc. (FDMT) May Report Negative Earnings: Know the Trend Ahead of Q1 Release [Yahoo! Finance]
Low
Report
4D Molecular Therapeutics, Inc. (FDMT) May Report Negative Earnings: Know the Trend Ahead of Q1 Release [Yahoo! Finance]
5/1
08:19 am
fdmt
4DMT Announces Presentations at ARVO 2024 Annual Meeting [Yahoo! Finance]
Medium
Report
4DMT Announces Presentations at ARVO 2024 Annual Meeting [Yahoo! Finance]
5/1
08:00 am
fdmt
4DMT Announces Presentations at ARVO 2024 Annual Meeting
Medium
Report
4DMT Announces Presentations at ARVO 2024 Annual Meeting
4/29
07:13 am
fdmt
4D Molecular Therapeutics: Catalysts With Pioneering Gene Therapy With Directed Evolution [Seeking Alpha]
Medium
Report
4D Molecular Therapeutics: Catalysts With Pioneering Gene Therapy With Directed Evolution [Seeking Alpha]
4/25
10:38 am
fdmt
Ophthalmics Collaboration and Licensing Deals Collection, 2019-2024: Leading Deals by Value, Most Active Dealmakers, Benchmark Analysis, Financial Terms, and More [Yahoo! Finance]
Low
Report
Ophthalmics Collaboration and Licensing Deals Collection, 2019-2024: Leading Deals by Value, Most Active Dealmakers, Benchmark Analysis, Financial Terms, and More [Yahoo! Finance]
4/15
01:18 pm
fdmt
4D Molecular Therapeutics, Inc. (NASDAQ: FDMT) had its price target raised by analysts at Royal Bank of Canada from $35.00 to $40.00. They now have an "outperform" rating on the stock.
Low
Report
4D Molecular Therapeutics, Inc. (NASDAQ: FDMT) had its price target raised by analysts at Royal Bank of Canada from $35.00 to $40.00. They now have an "outperform" rating on the stock.
4/15
08:11 am
fdmt
4D Molecular Therapeutics, Inc. (NASDAQ: FDMT) is now covered by analysts at Barclays PLC. They set an "overweight" rating and a $45.00 price target on the stock.
Low
Report
4D Molecular Therapeutics, Inc. (NASDAQ: FDMT) is now covered by analysts at Barclays PLC. They set an "overweight" rating and a $45.00 price target on the stock.
4/1
01:04 pm
fdmt
4D Molecular Therapeutics, Inc. (NASDAQ: FDMT) had its price target lowered by analysts at BMO Capital Markets from $70.00 to $63.00. They now have an "outperform" rating on the stock.
Low
Report
4D Molecular Therapeutics, Inc. (NASDAQ: FDMT) had its price target lowered by analysts at BMO Capital Markets from $70.00 to $63.00. They now have an "outperform" rating on the stock.
4/1
11:03 am
fdmt
4D Molecular Therapeutics, Inc. (NASDAQ: FDMT) had its price target raised by analysts at Jefferies Financial Group Inc. from $30.00 to $58.00. They now have a "buy" rating on the stock.
Low
Report
4D Molecular Therapeutics, Inc. (NASDAQ: FDMT) had its price target raised by analysts at Jefferies Financial Group Inc. from $30.00 to $58.00. They now have a "buy" rating on the stock.
3/28
08:09 am
fdmt
4DMT Announces Update on Regulatory Interactions and Development Path for 4D-710 for Treatment of Cystic Fibrosis [Yahoo! Finance]
Medium
Report
4DMT Announces Update on Regulatory Interactions and Development Path for 4D-710 for Treatment of Cystic Fibrosis [Yahoo! Finance]
3/28
08:00 am
fdmt
4DMT Announces Update on Regulatory Interactions and Development Path for 4D-710 for Treatment of Cystic Fibrosis
High
Report
4DMT Announces Update on Regulatory Interactions and Development Path for 4D-710 for Treatment of Cystic Fibrosis
3/8
10:41 am
fdmt
Co-development Deals in Pharmaceuticals and Biotechnology 2016 to 2024 Featuring 843 Market Players - Deals Listed by Company A-Z, Headline Value, Therapeutic Area, and Technology Type [Yahoo! Finance]
Low
Report
Co-development Deals in Pharmaceuticals and Biotechnology 2016 to 2024 Featuring 843 Market Players - Deals Listed by Company A-Z, Headline Value, Therapeutic Area, and Technology Type [Yahoo! Finance]
3/8
10:07 am
fdmt
Asset Purchase Deals in Pharmaceuticals and Biotechnology 2016-2024: Trends, Deal Structure, Leading Deals by Value, Most Active Dealmakers, and More [Yahoo! Finance]
Low
Report
Asset Purchase Deals in Pharmaceuticals and Biotechnology 2016-2024: Trends, Deal Structure, Leading Deals by Value, Most Active Dealmakers, and More [Yahoo! Finance]
3/7
11:19 am
fdmt
Pharmaceuticals and Biotechnology Co-promotion and Co-marketing Partnering Trends Report 2024: Analysis of Deals Signed by the World's Leading Life Science Companies Signed Since 2016 [Yahoo! Finance]
Neutral
Report
Pharmaceuticals and Biotechnology Co-promotion and Co-marketing Partnering Trends Report 2024: Analysis of Deals Signed by the World's Leading Life Science Companies Signed Since 2016 [Yahoo! Finance]
3/7
04:46 am
fdmt
Analysis of Co-promotion and Co-marketing Deals in Pharmaceuticals and Biotechnology Signed During 2016-2024 [Yahoo! Finance]
Medium
Report
Analysis of Co-promotion and Co-marketing Deals in Pharmaceuticals and Biotechnology Signed During 2016-2024 [Yahoo! Finance]
3/4
08:00 am
fdmt
4DMT to Participate in Upcoming Investor Conferences
Medium
Report
4DMT to Participate in Upcoming Investor Conferences